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Studies of patterns offailure and causes ofdeath have been undertaken based upon the WHO
histopathologic classification. In a randomized trial of thoracic irradiation ± chemotherapy
(hydroxyurea and CCNU), patterns of failure did not seem to differ by cell type; the largest
group was "death without progression." A subsequent clinical trial of thoracic irradiation ±
cranial irradiation permitted a more detailed evaluation. Patients with squamous cell carcinoma
had a higher rate of local failure than distant metastasis. Those with small cell carcinoma had a
lower local failure rate and a high rate of distant spread. Patients with adenocarcinoma and
large cell carcinoma had the lowest local failure rate, but had a high rate ofdistant metastasis.
In 300 consecutive patients with autopsies, 75 percent with squamous carcinoma died of
complications of the thoracic tumor and only one-quarter had extrathoracic dissemination; 30
percent with small cell carcinoma died of local tumor complications and 70 percent had
carcinomatosis; 40 percent of patients with adenocarcinoma and large cell carcinoma died of
intrathoracic complications, and 55 percent had distant metastases. Halfthe patients with small
cell carcinoma, large cell carcinoma, and adenocarcinoma had brain metastases at autopsy.
Future clinical trials should emphasize better control of the most common sites of failure.
Virtually all clinical studies, whether surgical, radiotherapeutic, or chemotherapeu-
tic, use survival as an endpoint. Although survival is an important parameter to
evaluate, it often does not provide information that would suggest better approaches
to treatment. When comparing different treatments, unless the groups ofpatients are
completely comparable with respect to important prognostic factors, survival may be
relatively meaningless.
In order to evaluate approaches to treatment ofcarcinoma ofthe lung in a manner
that might suggest ways to improve therapy, several studies were undertaken to
evaluate patterns of failure and causes of death. The first study attempted to
determine patterns of failure in a prospective randomized trial conducted by the
Veterans Administration Lung Group. This study has previously been reported [1,2].
It involved the comparison of standard radiation therapy (4000-5000 rad in four to
six weeks) to the primary pulmonary tumor and regional lymph nodes versus the
same irradiation plus hydroxyurea, I g/M2 twice weekly and CCNU, 100 mg/M2,
every six weeks, bothdrugs administered orally. Overall survival was not different for
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the two treatment groups (Fig. lA). Long-term survival ofpatients who lived at least
one year showed that treatment with irradiation alone was superior to combined
treatment (Fig. iB).
The study forms for this trial permitted evaluation of survival for the entire group
of patients. However, the forms were changed midway in the point ofthe trial so that
they included much more detailed information. Patterns of failure could only be
assessed from the study forms of the latter half of the trial. Table 1 shows the clinical
failure pattern by histopathologic type based on the final interpretation after review
by a three-member panel. Local failure was a common phenomenon regardless ofcell
type, as was distant spread. There was a suggestion that distant metastases were more
frequent in adenocarcinoma, but the numbers were too small to be significant. The
largest category was "death without progression." This group included all patients
who had no clinical metastases and stable ( < 50 percent regression or < 25 percent
progression) intrathoracic disease. This category prompted a search for a more
precise delineation ofcauses ofdeath. Final report forms included clinical assessment
of actual cause of death for a small number of patients but the numbers where this
information was available were too small to associate causes of death with specific
cell types.
In a more recently completed study, with larger numbers of patients and more
detailed report forms, it was possible more clearly to identify clinical patterns of
failure. The slides from this study were also reviewed by the three-member panel of
pathologists directed by Dr. Raymond Yesner. The results of this trial have been
published [3,4,5]. In order to permit comparisons among the cell types, each
histopathologic sample was normalized to 100 patients entering on study; squamous
cell carcinoma, small cell carcinoma, and the combined group of adenocarcinoma
and large cell carcinoma (between which there were no significant differences),
constituted the three sub-groups for comparison. Figure 2 shows thefailure sequence
for the patients with squamous carcinoma. It is apparent that local failure was a
common problem, both initially and subsequently. Initial failure by distant spread
occurred in 20 percent of patients, a small proportion of whom eventually also had
local failure. Death without clinical evidence ofprogression occurred in 23 percent of
patients. A similar set of 100 patients with small cell carcinoma(Fig. 3) is traced from
entry on study until the time of death. Local persistence or recurrence as the initial
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FIG. IA. Survival after randomization by treat- lived at least one year, by treatment group.
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TABLE 1
First Site of Progression (Clinical) by Cell Type After Irradiation i Chemotherapy VALG 13 L
Adenocar-
Site of Progression Squamous Small Cell cinoma Large Cell Total
Local 200o (17) 23% (7) 13% (4) 23% (9) 2007 (37)
Distant 21% (18) 29% (9) 40% (12) 28% (11) 27%o (50)
Multiple sites 5% (4) 0 3% (1) 5% (2) 407 (7)
Death without
progression 49% (41) 39% (12) 43% (13) 35% (14) 4307 (80)
Not failed 5% (4) 10% (3) 0 10% (4) 6%o (11)
( ) = Number of patients
type offailure was relatively infrequent, whereas distant metastases clearly predomi-
nated. However, a large proportion ofpatients failed both within the thorax and with
extra-thoracic disease. The combined group with adenocarcinoma and large cell
carcinoma had an intermediate failure pattern (Fig. 4). A small proportion of
patients failed locally when compared to squamous carcinoma. Distant metastases
were found almost as frequently as with small cell carcinoma and much more
frequently than with squamous cell carcinoma.
A review of the literature comparing clinical patterns offailure to autopsy data[6]
showed that the distributions of metastases were different and little could be said
about actual cause of death. The diagnosis of metastasis in some sites was associated
with a much shorter survival interval, but it was unclear whether this reflected clinical
detection very late in the course ofthe disease or relative effectiveness oftherapy once
metastases were documented. A report from Memorial Hospital in New York, based
on autopsy data, suggested that local factors were of considerable importance as the
immediate cause of death. However, comparisons by histopathologic subtype were
not undertaken [7].
In order to assess causes of death by cell type, a consecutive group of 300 patients
who came to autopsy and had been a part of VALG studies, was analyzed [8]. Of
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course, patients die as the result of several concomitant factors and separation of
these factors is somewhat arbitrary. In order to try to delineate the major factors
contributing to death, patients who died with any evidence of extrathoracic metas-
tases were said to have died from "carcinomatosis." The "CNS" patients had
metastatic disease confined to the central nervous system without any other evidence
of extrathoracic spread. The combination of infection, hemorrhage, and respiratory
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and cardiac failure could be taken as a measure of failure to overcome the
intrathoracic disease. This latter group of patients had no evidence of extrathoracic
metastasis. The results (Table 2) showed that a large proportion of patients with
squamous cell carcinoma died from complications of the local tumor, while a very
high proportion of patients with small cell carcinoma had extrathoracic dissemina-
tion documented at autopsy. Again, adenocarcinoma and large cell carcinoma were
intermediate in regard to local factors and carcinomatosis when compared to
squamous cell carcinoma and small cell carcinoma.
Brain metastases can be considered separately for the individual cell types for two
reasons. The central nervous system represents a "sanctuary" area which is relatively
poorly penetrated by cytotoxic agents. Even the most sensitive cell type to chemo-
therapeutic agents, small cell carcinoma, was unaffected in regard to frequency of
CNS metastasis when comparing the lipid soluble nitrosoureas to other chemothera-
peutic agents [9]. Second; prophylactic cranial irradiation has been tried and found
to be tolerated and might be considered for any group of patients at sufficiently high
risk to justify this approach [3]. Table 3 shows the frequency of brain metastasis as
determined in 400 consecutive autopsies of patients with cancer of the lung in which
the brain was examined. Approximately 50 percent plus or minus 5 percent of
patients with small cell carcinoma, large cell carcinoma, and adenocarcinoma have
brain metastasis at autopsy. When patients are evaluated according to whether the
brain metastasis occurred concomitant with other metastases as opposed to the brain
being the only site of metastasis (Table 4), adenocarcinoma seems to be different in
that single organ brain metastases are found in over 10 percent of patients. This
suggests that prophylactic cranial irradiation should be more extensively investigated
in patients with adenocarcinoma, and perhaps thosewith large cell carcinoma. It also
suggests that survival is not likely to be altered bythe prophylactic cranial irradiation
except, perhaps, in patients with adenocarcinoma where this may represent the only
site of distant spread. In fact, recently completed studies have shown that prophylac-
tic irradiation with low total doses has reduced the frequency of brain metastasis in
patients with "non-small cell" carcinoma ofthe lung[5]. Although long-term survival
data are not available, a favorable effect on survival might be expected in patients
with adenocarcinoma. In the other patients, CNS metastases co-exist with other sites
of dissemination, and improved survival from prophylactic irradiation would be
unlikely.
TABLE 2
Causes of Death by Cell Type: 300 Consecutive VALG Autopsies
Cause of Death Squamous Small Cell Adenocarcinoma Large Cell Combined
Carcinomatosis 25% (21) 70% (40) 48%o (49) 47%o (23) (2)
CNS 2% (2) - 9%70 (9) 8%7o (4) -
Infection 36%o (30) 11% (6) 190% (19) 27%o (13) (6)
Hemorrhage 8%7o (7) 7% (4) 4% (4) 2% (1) -
Respiratory failure 6%7o (5) 30/o (2) 7%70 (7) 8%o (4) -
Heart failure 20%7o (17) 9%o (5) 8%o (8) 6% (3) -
Pulmonary emboli - - 40o (4) 2% (1) -
Other malignancy 1% (1) - 2% (2) -
( ) = Number of patients
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TABLE 3
Frequency of Brain Metastases by Cell Type 400 Autopsies from VALG and West Haven VA Hospital
Brain Metastases
Cell Type (No. cases) Number No of total brain mets No of cell type
Squamous (123) 16 10.5 13.0
Small cell (82) 37 24.2 45.1
Adenocarcinoma (129) 69 45.1 53.5
Large cell (54) 28 18.3 52.0
Combined (12) 3 1.9 25.0
Total 153 100.0
TABLE 4
Frequency of Brain Metastases Alone at Autopsy by Cell Type
Brain Metastases
Cell Type Number N of total brain mets % of cell type
Squamous 5 16.1 4.1
Small cell 5 16.1 6.1
Adenocarcinoma 16 51.7 12.4
Large cell 5 16.1 9.3
Total 31 100.0
In summary, clinical patterns of failure, as well as patterns offailure and causes of
death determined from autopsies, suggest three basic groups of patients with
carcinoma of the lung. Those with squamous cell carcinoma have progression of
disease within the thorax and are most likely to die as a result ofcompromise ofvital
intrathoracic organs. It is justifiable in these patients to pursue vigorous efforts to
control the local-regional disease. Higher doses of irradiation, radiotherapy plus
hypoxic cell sensitizers, and high LET (linear energy transfer) radiations such as
neutrons deserve investigation. Patients with small cell carcinoma are subject to
widespread dissemination early in the course of the disease. It is now recognized that
systemic chemotherapy is an important part ofthe management ofthese patients as is
prophylactic cranial irradiation and thoracic irradiation. Patients with large cell
carcinoma and adenocarcinoma are at high risk for failure both within the thorax
and in extrathoracic sites. Adenocarcinoma is especially likely to disseminate to the
brain, perhaps as the only site of spread. Prophylactic cranial irradiation may be
especially helpful in these patients. In addition, continued search for effective
combinations of chemotherapeutic agents is important as it is clear that many
patients will require systemic treatment.
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